Last reviewed · How we verify
Transdermal Contraceptive System — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Transdermal Contraceptive System (Transdermal Contraceptive System) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Transdermal Contraceptive System TARGET | Transdermal Contraceptive System | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Transdermal Contraceptive System CI watch — RSS
- Transdermal Contraceptive System CI watch — Atom
- Transdermal Contraceptive System CI watch — JSON
- Transdermal Contraceptive System alone — RSS
Cite this brief
Drug Landscape (2026). Transdermal Contraceptive System — Competitive Intelligence Brief. https://druglandscape.com/ci/transdermal-contraceptive-system. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab